Does the media favor DNTH or VTRS?

In the previous week, Dianthus Therapeutics had 5 more articles in the media than Viatris. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 5 mentions for Viatris. Dianthus Therapeutics' average media sentiment score of 1.39 beat Viatris' score of 0.39 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DNTH or GMAB?

In the previous week, Dianthus Therapeutics had 5 more articles in the media than Genmab A/S. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 5 mentions for Genmab A/S. Dianthus Therapeutics' average media sentiment score of 1.39 beat Genmab A/S's score of 1.06 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BBIO or DNTH?

In the previous week, BridgeBio Pharma had 1 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 11 mentions for BridgeBio Pharma and 10 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.39 beat BridgeBio Pharma's score of 1.30 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DNTH or ASND?

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 13 mentions for Ascendis Pharma A/S and 10 mentions for Dianthus Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.51 beat Dianthus Therapeutics' score of 1.39 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor DNTH or ELAN?

In the previous week, Dianthus Therapeutics had 1 more articles in the media than Elanco Animal Health. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 9 mentions for Elanco Animal Health. Dianthus Therapeutics' average media sentiment score of 1.39 beat Elanco Animal Health's score of 0.72 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Dianthus Therapeutics (DNTH) Competitors

$106.92 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$108.26 +1.34 (+1.25%)

As of 07/31/2026 07:34 PM Eastern

Compare

DNTH vs. VTRS, GMAB, BBIO, ASND, and ELAN

Should you buy Dianthus Therapeutics stock or one of its competitors? MarketBeat compares Dianthus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dianthus Therapeutics include Viatris (VTRS), Genmab A/S (GMAB), BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), and Elanco Animal Health (ELAN).

How does Dianthus Therapeutics compare to Viatris?

Dianthus Therapeutics (NASDAQ:DNTH) and Viatris (NASDAQ:VTRS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

In the previous week, Dianthus Therapeutics had 5 more articles in the media than Viatris. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 5 mentions for Viatris. Dianthus Therapeutics' average media sentiment score of 1.39 beat Viatris' score of 0.39 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dianthus Therapeutics presently has a consensus target price of $117.82, suggesting a potential upside of 10.19%. Viatris has a consensus target price of $17.50, suggesting a potential downside of 0.34%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Dianthus Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Dianthus Therapeutics has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$1.34M	4,374.92	-$162.34M	-$4.13	N/A
Viatris	$14.56B	1.40	-$3.51B	-$0.26	N/A

Viatris has a net margin of -2.04% compared to Dianthus Therapeutics' net margin of -12,998.50%. Viatris' return on equity of 19.04% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Viatris	-2.04%	19.04%	7.62%

Dianthus Therapeutics has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Viatris has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 0.3% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Dianthus Therapeutics beats Viatris on 11 of the 17 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Genmab A/S?

Dianthus Therapeutics (NASDAQ:DNTH) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

Dianthus Therapeutics currently has a consensus target price of $117.82, suggesting a potential upside of 10.19%. Genmab A/S has a consensus target price of $39.28, suggesting a potential upside of 36.05%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

In the previous week, Dianthus Therapeutics had 5 more articles in the media than Genmab A/S. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 5 mentions for Genmab A/S. Dianthus Therapeutics' average media sentiment score of 1.39 beat Genmab A/S's score of 1.06 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a net margin of 21.05% compared to Dianthus Therapeutics' net margin of -12,998.50%. Genmab A/S's return on equity of 15.34% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Genmab A/S	21.05%	15.34%	8.94%

Dianthus Therapeutics has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$1.34M	4,374.92	-$162.34M	-$4.13	N/A
Genmab A/S	$3.90B	4.61	$963M	$1.32	21.87

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Dianthus Therapeutics and Genmab A/S tied by winning 8 of the 16 factors compared between the two stocks.

How does Dianthus Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Dianthus Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$579.96M	27.00	-$724.93M	-$3.74	N/A
Dianthus Therapeutics	$1.34M	4,374.92	-$162.34M	-$4.13	N/A

In the previous week, BridgeBio Pharma had 1 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 11 mentions for BridgeBio Pharma and 10 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.39 beat BridgeBio Pharma's score of 1.30 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dianthus Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

BridgeBio Pharma has a net margin of -124.42% compared to Dianthus Therapeutics' net margin of -12,998.50%. BridgeBio Pharma's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BridgeBio Pharma currently has a consensus price target of $95.21, suggesting a potential upside of 18.88%. Dianthus Therapeutics has a consensus price target of $117.82, suggesting a potential upside of 10.19%. Given BridgeBio Pharma's higher possible upside, equities analysts plainly believe BridgeBio Pharma is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

BridgeBio Pharma beats Dianthus Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Ascendis Pharma A/S?

Dianthus Therapeutics (NASDAQ:DNTH) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Dianthus Therapeutics currently has a consensus target price of $117.82, indicating a potential upside of 10.19%. Ascendis Pharma A/S has a consensus target price of $296.72, indicating a potential upside of 21.65%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05

Ascendis Pharma A/S has a net margin of 57.87% compared to Dianthus Therapeutics' net margin of -12,998.50%. Ascendis Pharma A/S's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

47.5% of Dianthus Therapeutics shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dianthus Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

Dianthus Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$1.34M	4,374.92	-$162.34M	-$4.13	N/A
Ascendis Pharma A/S	$814.57M	18.68	-$258M	$8.67	28.13

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 13 mentions for Ascendis Pharma A/S and 10 mentions for Dianthus Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.51 beat Dianthus Therapeutics' score of 1.39 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Ascendis Pharma A/S beats Dianthus Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Elanco Animal Health?

Dianthus Therapeutics (NASDAQ:DNTH) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Dianthus Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$1.34M	4,374.92	-$162.34M	-$4.13	N/A
Elanco Animal Health	$4.89B	2.70	-$232M	-$0.50	N/A

Dianthus Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

Dianthus Therapeutics presently has a consensus price target of $117.82, indicating a potential upside of 10.19%. Elanco Animal Health has a consensus price target of $28.73, indicating a potential upside of 8.72%. Given Dianthus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dianthus Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Elanco Animal Health has a net margin of -4.95% compared to Dianthus Therapeutics' net margin of -12,998.50%. Elanco Animal Health's return on equity of 7.42% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Elanco Animal Health	-4.95%	7.42%	3.66%

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Dianthus Therapeutics had 1 more articles in the media than Elanco Animal Health. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 9 mentions for Elanco Animal Health. Dianthus Therapeutics' average media sentiment score of 1.39 beat Elanco Animal Health's score of 0.72 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Dianthus Therapeutics beats Elanco Animal Health on 9 of the 16 factors compared between the two stocks.

Get Dianthus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNTH vs. The Competition

Export

Metric	Dianthus Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.84B	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-25.89	7.38	282.30	24.66
Price / Sales	4,374.92	1,200.34	563.12	75.93
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	9.37	16.96	10.96	6.07
Net Income	-$162.34M	-$12.56M	$3.49B	$347.99M
7 Day Performance	2.33%	-1.77%	-0.64%	-0.44%
1 Month Performance	13.33%	-8.39%	-5.23%	-4.81%
1 Year Performance	419.28%	48.40%	61.97%	18.61%

Dianthus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNTH Dianthus Therapeutics	2.1214 of 5 stars	$106.92 flat	$117.82 +10.2%	+419.3%	$5.84B	$1.34M	N/A	80	Positive News Upcoming Earnings Gap Up
VTRS Viatris	2.2231 of 5 stars	$17.59 +3.5%	$17.50 -0.5%	+99.3%	$19.79B	$14.30B	N/A	30,000	Upcoming Earnings
GMAB Genmab A/S	4.6668 of 5 stars	$28.36 +1.6%	$38.21 +34.7%	+32.6%	$17.40B	$3.72B	21.49	3,029	Positive News Upcoming Earnings
BBIO BridgeBio Pharma	3.3152 of 5 stars	$82.45 +2.1%	$95.21 +15.5%	+69.1%	$15.82B	$502.08M	N/A	400	Positive News Upcoming Earnings Gap Up
ASND Ascendis Pharma A/S	4.8256 of 5 stars	$255.20 +1.4%	$295.67 +15.9%	+39.8%	$15.70B	$814.57M	29.43	1,189	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DNTH) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dianthus Therapeutics (DNTH) Competitors

DNTH vs. VTRS, GMAB, BBIO, ASND, and ELAN

How does Dianthus Therapeutics compare to Viatris?

Summary

How does Dianthus Therapeutics compare to Genmab A/S?

Summary

How does Dianthus Therapeutics compare to BridgeBio Pharma?

Summary

How does Dianthus Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Dianthus Therapeutics compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH vs. The Competition

Dianthus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dianthus Therapeutics (DNTH) Competitors

DNTH vs. VTRS, GMAB, BBIO, ASND, and ELAN

How does Dianthus Therapeutics compare to Viatris?

Does the media favor DNTH or VTRS?

Do analysts rate DNTH or VTRS?

Which has higher earnings & valuation, DNTH or VTRS?

Is DNTH or VTRS more profitable?

Which has more risk & volatility, DNTH or VTRS?

Do insiders and institutionals hold more shares of DNTH or VTRS?

Summary

How does Dianthus Therapeutics compare to Genmab A/S?

Do analysts rate DNTH or GMAB?

Does the media favor DNTH or GMAB?

Is DNTH or GMAB more profitable?

Which has more volatility & risk, DNTH or GMAB?

Which has preferable valuation & earnings, DNTH or GMAB?

Do institutionals & insiders hold more shares of DNTH or GMAB?

Summary

How does Dianthus Therapeutics compare to BridgeBio Pharma?

Which has preferable earnings and valuation, BBIO or DNTH?

Does the media prefer BBIO or DNTH?

Which has more volatility and risk, BBIO or DNTH?

Is BBIO or DNTH more profitable?

Do institutionals and insiders have more ownership in BBIO or DNTH?

Do analysts rate BBIO or DNTH?

Summary

How does Dianthus Therapeutics compare to Ascendis Pharma A/S?

Do analysts prefer DNTH or ASND?

Is DNTH or ASND more profitable?

Do insiders & institutionals hold more shares of DNTH or ASND?

Which has more volatility and risk, DNTH or ASND?

Which has preferable valuation and earnings, DNTH or ASND?

Does the media prefer DNTH or ASND?

Summary

How does Dianthus Therapeutics compare to Elanco Animal Health?

Which has stronger earnings & valuation, DNTH or ELAN?

Which has more risk & volatility, DNTH or ELAN?

Do analysts prefer DNTH or ELAN?

Is DNTH or ELAN more profitable?

Do insiders and institutionals hold more shares of DNTH or ELAN?

Does the media favor DNTH or ELAN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH vs. The Competition

Dianthus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools